Actively Recruiting

Age: 18Years +
All Genders
ID06926179

Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer: A Multicenter Real-World Study

Led by Peking University Cancer Hospital & Institute · Updated on 2025-04-16

500

Participants Needed

4

Research Sites

104 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the safety, effectiveness, and survival results of neoadjuvant or induction immunotherapy in patients with non-small cell lung cancer (NSCLC). This study focuses on real-world outcomes across multiple centers, including patients undergoing surgery, definitive radiotherapy, or non-surgical treatments. It aims to fill gaps left by previous trials by including a diverse patient group, covering treatment from the initial immunotherapy phase through surgery and follow-up, to better support clinical decisions for both operable and inoperable cases. The study observes patients who have received neoadjuvant immune checkpoint inhibitors, such as PD-1/PD-L1 blockers, either alone or combined with chemotherapy. All treatments, including surgery and radiotherapy, follow routine care as determined by the patients' doctors. This retrospective observational design collects data on various treatment paths to assess outcomes in normal clinical practice. Participants' medical records are reviewed to analyze technical surgical difficulty, disease-free survival, postoperative complications, treatment-related adverse events, and other key clinical outcomes. The study includes follow-up periods of up to five years to monitor progression-free and overall survival. This comprehensive data collection helps provide real-world evidence on the benefits and risks of neoadjuvant immunotherapy in NSCLC management.

CONDITIONS

Brief Title

Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Histologically confirmed non-small cell lung cancer (NSCLC), regardless of EGFR or ALK mutations
  • Clinical stage IA to IIIC according to AJCC 8th Edition before neoadjuvant treatment
  • Received at least one cycle of neoadjuvant immunotherapy, with or without chemotherapy
  • Assessed as resectable or potentially resectable by surgical experts before treatment
Not Eligible

You will not qualify if you...

  • Confirmed stage M1 disease
  • History of previous lung cancer or other metastatic cancers
  • Participation in other randomized controlled trials involving neoadjuvant treatment
  • Significant missing clinical data

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - Varies depending on treatment course

Participants receive neoadjuvant immunotherapy, with or without chemotherapy, as part of routine clinical care before surgery or radiotherapy.

Visits occur as part of routine care during neoadjuvant therapy

Surgery and Immediate Post-operative Care

Duration - Day of surgery and up to 30 days post-surgery

Participants undergo radical surgery with assessment of perioperative safety and surgical outcomes.

1 surgery day visit and approximately 6 post-operative visits

Post-operative Follow-up

Duration - Up to 5 years after surgery

Participants are monitored for disease-free survival and treatment-related adverse events up to 5 years after surgery.

Regular follow-up visits over 5 years

Trial Site Locations

Total: 4 locations

1

Peking University Cancer Hospital & Institute

Beijing, Beijing Municipality, China, 100142

Actively Recruiting

2

Peking University Third Hospital

Beijing, Beijing Municipality, China

Actively Recruiting

3

Inner Mongolia Hospital of Peking University Cancer Hospital

Hohhot, Inner Mongolia, China

Actively Recruiting

4

The Third Affliated Hospital of Kunming Medical University

Kunming, Yunnan, China

Actively Recruiting

Loading map...

Research Team

N

Nan Wu, MD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Similar Trials

A National Multicenter, Randomized, Placebo-Controlled Phase...

Rectal Cancer

Actively Recruiting

1 location

A Phase II Study Evaluating Stereotactic Radiotherapy for Ol...

Metastatic Renal Cell Carcinoma

Actively Recruiting

30 locations

A Study Exploring Beta-Hydroxybutyrate Supplementation with ...

Rectal Cancer

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here